# Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

> **NCT01934894** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 11 (actual)

## Conditions studied

- Metastatic Breast Cancer With Intracranial Metastases

## Interventions

- **DRUG:** cabazitaxel
- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT01934894
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2016-02
- **Final completion:** 2017-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study was terminated due to lack of significant signal of efficacy
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934894, "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01934894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*